Canbiola, Inc. (OTCQB: CANB) Expects Strong Revenue Growth from Q3 to Q4 2018 as President Trump Signs Farm Bill Legalizing Hemp CBD NationwidePress Release | 12/24/2018
HICKSVILLE, NY, Dec. 24, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Based upon a strong product demand, Canbiola (OTCQB: CANB) is on the path toward significant revenue growth. The Company has made significant investment in development of its nationwide distribution infrastructure through Its doctor and medical office network and expects this forward movement to continue. This trend is even potentially more impactful with President Trump signing of the 2018 Farm Bill. The 2018 Farm Bill removed CBD derived hemp from the Schedule 1 drug list and makes hemp CBD Federally legal for use, interstate transporting, and export. Hemp based CBD with under .3% THC (the psychoactive ingredient in marijuana) has proven to be medically beneficial in a regimen of wellness and pain relief programs.
“We believe we are in the right place at the right time with our public company offering a variety of CBD products under our proprietary formulation from the laboratory and production facility in Washington State,” states Canbiola’s CEO, Marco Alfonsi. “We have previously made several announcements regarding our growing number of doctors on our Medical Advisory board as well as our Corporate Advisory Board and with their guidance and some specialty production equipment in the WA facility, we expect to announce numerous new product opportunities.”
According to a new article from Rolling Stone, The CBD market is expected to grow to $22 billion by 2022, see https://www.rollingstone.com/culture/culture-...22-722852/
From the Rolling Stone article: “CBD, a non-psychoactive cannabinoid found in cannabis, has had a surge in popularity over the past couple of years. Unlike THC, the chemical compound that gives weed its signature effect, CBD has been shown to help with everything from PTSD and anxiety to MS and epilepsy — without getting you high.”
Mr. Alfonsi concludes, “2019 is positioned to be a banner year for Canbiola as we have many new efforts underway and believe these efforts and investments will bear fruit. Canbiola’s entire product offering is 100% Federally legal.”
The Canbiola family wishes everyone a happy holiday and a healthy and safe New Year.
About Canbiola, Inc.:
Canbiola, Inc. is a public company trading under symbol CANB.
Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. The company has already launched several products found at www.canbiola.com.
CONTACT INFORMATION:
Canbiola Investor Relations
Email: IR@canbiola.com
Phone: (516) 595-9544
Website: http://www.canbiola.com
Follow us on Twitter and Facebook
HICKSVILLE, NY, Dec. 24, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Based upon a strong product demand, Canbiola (OTCQB: CANB) is on the path toward significant revenue growth. The Company has made significant investment in development of its nationwide distribution infrastructure through Its doctor and medical office network and expects this forward movement to continue. This trend is even potentially more impactful with President Trump signing of the 2018 Farm Bill. The 2018 Farm Bill removed CBD derived hemp from the Schedule 1 drug list and makes hemp CBD Federally legal for use, interstate transporting, and export. Hemp based CBD with under .3% THC (the psychoactive ingredient in marijuana) has proven to be medically beneficial in a regimen of wellness and pain relief programs.
“We believe we are in the right place at the right time with our public company offering a variety of CBD products under our proprietary formulation from the laboratory and production facility in Washington State,” states Canbiola’s CEO, Marco Alfonsi. “We have previously made several announcements regarding our growing number of doctors on our Medical Advisory board as well as our Corporate Advisory Board and with their guidance and some specialty production equipment in the WA facility, we expect to announce numerous new product opportunities.”
According to a new article from Rolling Stone, The CBD market is expected to grow to $22 billion by 2022, see https://www.rollingstone.com/culture/culture-...22-722852/
From the Rolling Stone article: “CBD, a non-psychoactive cannabinoid found in cannabis, has had a surge in popularity over the past couple of years. Unlike THC, the chemical compound that gives weed its signature effect, CBD has been shown to help with everything from PTSD and anxiety to MS and epilepsy — without getting you high.”
Mr. Alfonsi concludes, “2019 is positioned to be a banner year for Canbiola as we have many new efforts underway and believe these efforts and investments will bear fruit. Canbiola’s entire product offering is 100% Federally legal.”
The Canbiola family wishes everyone a happy holiday and a healthy and safe New Year.
About Canbiola, Inc.:
Canbiola, Inc. is a public company trading under symbol CANB.
Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. The company has already launched several products found at www.canbiola.com.
CONTACT INFORMATION:
Canbiola Investor Relations
Email: IR@canbiola.com
Phone: (516) 595-9544
Website: http://www.canbiola.com
Follow us on Twitter and Facebook
